This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
FDA approves tamoxifen to reduce breast cancer risk
The FDA cleared tamoxifen for healthy women at very high risk to cut cancer odds. It lowers risk by 44 percent in high risk groups but raises serious side effects including uterine cancer, clots, and cataracts. Doctors must weigh benefits and risks and educate patients before use.
MENTIONED IN THIS ARTICLE
Washington
Food and Drug Administration
FDA
Michael Friedman
Kathy Albain
Loyola University Medical School
Albain
National Cancer Institute
Zeneca Inc
Harmon Eyre
American Cancer Society